Drug Profile
Slameterol/fluticasone propionate - Viatris
Alternative Names: MGR-001; Salmeterol xinafoate/fluticasone propionate - ViatrisLatest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Mylan
- Developer Viatris Inc
- Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for phase-I development in Asthma(In adolescents, In adults) in United Kingdom (Inhalation)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In adolescents, In adults) in United Kingdom (Inhalation)
- 19 Sep 2019 Slameterol/fluticasone propionate is still in phase I trial in United Kingdom